Literature DB >> 12488666

Hospitalizations during a measles epidemic in the Netherlands, 1999 to 2000.

Susan Van Den Hof1, Colette Smit, Jim E Van Steenbergen, Hester E De Melker.   

Abstract

BACKGROUND: A measles epidemic occurred in the Netherlands in 1999 to 2000. We collected data on hospitalized and deceased cases to inform the public about the risks associated with measles infection.
METHODS: From the National Medical Registration we extracted hospital discharge diagnoses for measles-related hospitalizations (International Classification of Diseases, 9th revision, Clinical Modification Code 055) during the measles epidemic (April 1999 to May 2000). We also reviewed hospital records to assess reasons for hospitalization and severity of disease as a result of measles infection during this epidemic. In addition we estimated the total number of hospitalized cases by a capture-recapture approach using two surveillance sources.
RESULTS: Measles without mention of complication (39%) and postmeasles pneumonia (33%) were most often registered as main discharge diagnoses for the 130 cases in the National Medical Registration. Forty-seven (96%) of the 49 patients whose hospital charts were reviewed were not vaccinated. Median admission period was 5 (range, 1 to 26) days, 19 (38%) required mechanical ventilation and 14 (29%) had sequelae at the time of discharge but none was permanent. Three patients died as a result of complications. No association was observed between preexisting illness and either reason for admission (P = 0.5) or residual symptoms at discharge (P = 0.5). The estimated total number of hospitalized measles patients was 157 (95% confidence interval, 145 to 179), leading to an estimated 825 admission days during an epidemic in which 3,292 cases were reported.
CONCLUSIONS: Measles infection can still run a severe course even in a prosperous country.

Entities:  

Mesh:

Year:  2002        PMID: 12488666     DOI: 10.1097/00006454-200212000-00012

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau.

Authors:  May-Lill Garly; Carlitos Balé; Cesário Lourenco Martins; Hilton C Whittle; Jens Nielsen; Ida M Lisse; Peter Aaby
Journal:  BMJ       Date:  2006-10-23

2.  Current trends of immunization in Nigeria: prospect and challenges.

Authors:  Endurance A Ophori; Musa Y Tula; Azuka V Azih; Rachel Okojie; Precious E Ikpo
Journal:  Trop Med Health       Date:  2014-04-23

3.  Economic Costs of Measles Outbreak in the Netherlands, 2013-2014.

Authors:  Anita W M Suijkerbuijk; Tom Woudenberg; Susan J M Hahné; Laura Nic Lochlainn; Hester E de Melker; Wilhelmina L M Ruijs; Anna K Lugnér
Journal:  Emerg Infect Dis       Date:  2015-11       Impact factor: 6.883

4.  Media representation of vaccine side effects and its impact on utilization of vaccination services in Vietnam.

Authors:  Bach Xuan Tran; Victoria L Boggiano; Long Hoang Nguyen; Carl A Latkin; Huong Lan Thi Nguyen; Tung Thanh Tran; Huong Thi Le; Thuc Thi Minh Vu; Cyrus Sh Ho; Roger Cm Ho
Journal:  Patient Prefer Adherence       Date:  2018-09-06       Impact factor: 2.711

5.  Indirect costs associated with deaths of children aged 0-14 years from measles in a weak health system and conflict and fragile zone: the case of Somalia.

Authors:  Omar B Da'ar
Journal:  Epidemiol Infect       Date:  2019-08-09       Impact factor: 2.451

6.  Inpatient morbidity and mortality of measles in the United States.

Authors:  Raj Chovatiya; Jonathan I Silverberg
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

7.  Health burden and economic impact of measles-related hospitalizations in Italy in 2002-2003.

Authors:  Antonietta Filia; Antonio Brenna; Augusto Panà; Gianluca Maggio Cavallaro; Marco Massari; Marta L Ciofi degli Atti
Journal:  BMC Public Health       Date:  2007-07-24       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.